Investor Outlook: Sensyne Health Plc (LON:SENS) Buy Rating Reconfirmed at Peel Hunt Today

Sensyne Health Plc (LON:SENS) Rating Reaffirmed

Sensyne Health Plc (LON:SENS) shares have had their Buy Rating reiterated by analysts at Peel Hunt in a research note issued to investors and clients on Wednesday morning.

The stock increased 1.08% or GBX 2 during the last trading session, reaching GBX 188. About 50,427 shares traded. Sensyne Health plc (LON:SENS) has 0.00% since November 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Sensyne Health plc, a healthcare technology company, engages in developing digital health software products in the United Kingdom. The company has market cap of 241.72 million GBP. The Company’s products include SEND, an early warning system that allows healthcare professionals to record vital sign observations, including blood pressure, pulse rate, oxygen saturation, temperature, respiratory rate, responsiveness, the presence of an oxygen mask, and a reason for concern by the nurse taking the observations; EDGE:COPD, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; GDm-Health, a patient-to-clinician system for the management of diabetes in pregnancy; and Support-HF, a digital health software system that underpins a remote patient management service for heart failure patients. It currently has negative earnings. The firm also offers CleanSpace, a software/device combination product for monitoring personal exposure to air pollution.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.